TD Securities upgraded shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) from a hold rating to a buy rating in a report released on Wednesday, November 8th, StockTargetPrices.com reports. The firm currently has C$25.50 price objective on the specialty pharmaceutical company’s stock.
Separately, Royal Bank Of Canada reduced their target price on shares of Valeant Pharmaceuticals International to C$22.50 and set a sector perform rating for the company in a research note on Friday, October 20th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Valeant Pharmaceuticals International presently has a consensus rating of Hold and a consensus price target of C$22.50.
Valeant Pharmaceuticals International (TSE:VRX) traded down C$0.17 on Wednesday, hitting C$18.28. 927,257 shares of the company were exchanged, compared to its average volume of 1,432,179. Valeant Pharmaceuticals International has a 1-year low of C$11.20 and a 1-year high of C$25.22.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2017/11/17/valeant-pharmaceuticals-intl-inc-vrx-lifted-to-buy-at-td-securities.html.
In other Valeant Pharmaceuticals International news, Director Schutter Richard Urbain De acquired 4,900 shares of Valeant Pharmaceuticals International stock in a transaction dated Monday, August 21st. The stock was bought at an average cost of C$14.35 per share, for a total transaction of C$70,315.00.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.